adult onset diabetes Diabetes type 2
Conditions
Interventions
After inclusion, subjects will be randomised and blinded to 16 weeks of
progressive 30-45 min cycle ergometer interval training, applied 3 times a week
while breathing either hyperoxic (100%O2, 4-8
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Type 2 diabetes according to WHO criteria for over 2 years VO2peak 60-90% of age-predicted value as measured on a cycle-ergometer Motivated and willing/able to travel 3 times a week to ErasmusMC and participate in a supervised exercise intervention program.
Exclusion criteria
Exclusion criteria: Use of Beta-blocker therapy, low molecular heparin, exogenous insulin therapy (for exercise intervention only), use of oral anti-coagulans therapy; decompensatio cordis, angina pectoris, myocardial infarction or positive signs of cardiac ischaemia on the ECG during the incremental exercise test;orthopaedic impairments that would limit participation in the training program; co-morbidity such as renal failure or > grade III retinopathy or previous diabetic foot ulcer; Cerebro-vascular disease (CVA), neurological diseases or deficits. A history of glaucoma or high intraocular pressure will be contraindication for dilated fundus reflex photography
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relative improvement in whole-body insulin sensitivity. An insulin sensitivity index (SI) will be calculated by using the minimal model (Bergman et al 1985); a higher SI indicates enhanced insulin sensitivity. Acute-phase insulin secretion (AIRG) and glucose effectiveness (SG) were also determined from the IVGTT ( Bergman et al 1985). | — |
Secondary
| Measure | Time frame |
|---|---|
| Relative improvements in vascular function parameters using forearm plethysmography (change in forearmbloodflow in ml/100g forearm/min na nitriprusside/acetylcholine), cardiovascular fitness (VO2max), systemic blood pressure, body composition, lipid metabolism and glycemic control. | — |
Countries
Netherlands
Outcome results
None listed